The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats

Journal of Molecular and Cellular Cardiology

Volumn 92, Issue , 2016, Pages 96-104

  Martínez Martínez, Ernesto ^a   Rodríguez, Cristina ^b   Galán, María ^b   Miana, María ^a   Jurado López, Raquel ^a   Bartolomé, María Visitación ^a   Luaces, María ^c   Islas, Fabián ^c   Martínez González, José ^b   López Andrés, Natalia ^d   Cachofeiro, Victoria ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Institut Català de Ciències Cardiovasculars   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

Fibrosis; Leptin; Lysyl oxidase; Obesity

Indexed keywords

3 AMINOPROPIONITRILE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; LEPTIN; PROTEIN KINASE B; PROTEIN LYSINE 6 OXIDASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET INDUCED OBESITY; DISEASE ASSOCIATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; LIPID DIET; MALE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BIOSYNTHESIS; BLOOD PRESSURE; CARDIAC MUSCLE; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OBESITY; PATHOLOGY;

AMINOPROPIONITRILE; ANIMALS; AORTA; BLOOD PRESSURE; BODY WEIGHT; DIET, HIGH-FAT; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; LEPTIN; MYOCARDIUM; OBESITY; PROTEIN-LYSINE 6-OXIDASE; RATS; REACTIVE OXYGEN SPECIES;

EID: 84957567050     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.01.012     Document Type: Article

References (47)

1. Finucane M.M., Stevens G.A., Cowan M.J., Danaei G., Lin J.K., Paciorek C.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
2. Yan L.L., Daviglus M.L., Liu K., Stamler J., Wang R., Pirzada A., et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006, 295:190-198.
3. Fedak P.W., Verma S., Weisel R.D., Li R.K. Cardiac remodeling and failure: from molecules to man (part II). Cardiovasc. Pathol. 2005, 14:49-60.
4. Miner E.C., Miller W.L. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin. Proc. 2006, 81:71-76.
5. Laurent S., Mousseaux E., Boutouyrie P. Arterial stiffness as an imaging biomarker: are all pathways equal?. Hypertension 2013, 62:10-12.
6. Redon J., Cifkova R., Laurent S., Nilsson P., Narkiewicz K., Erdine S., et al. Mechanisms of hypertension in the cardiometabolic syndrome. J. Hypertens. 2009, 27:441-451.
7. Rodriguez C., Martinez-Gonzalez J., Raposo B., Alcudia J.F., Guadall A., Badimon L. Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc. Res. 2008, 79:7-13.
8. Rodriguez C., Rodriguez-Sinovas A., Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect. 2008, 21:218-224.
9. Rodriguez C., Raposo B., Martinez-Gonzalez J., Casani L., Badimon L. Low density lipoproteins downregulate lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1409-1414.
10. Saad F.A., Torres M., Wang H., Graham L. Intracellular lysyl oxidase: effect of a specific inhibitor on nuclear mass in proliferating cells. Biochem. Biophys. Res. Commun. 2010, 396:944-949.
11. Desmouliere A., Darby I., Costa A.M., Raccurt M., Tuchweber B., Sommer P., et al. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab. Investig. 1997, 76:765-778.
12. Miana M., Galan M., Martinez-Martinez E., Varona S., Jurado-Lopez R., Bausa-Miranda B., et al. The lysyl oxidase inhibitor beta-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. Disease Models & Mechanisms 2015, 8:543-551.
13. Di Donato A., Ghiggeri G.M., Di Duca M., Jivotenko E., Acinni R., Campolo J., et al. Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy. Nephron 1997, 76:192-200.
14. Sivakumar P., Gupta S., Sarkar S., Sen S. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol. Cell. Biochem. 2008, 307:159-167.
15. Sibon I., Sommer P., Lamaziere J.M., Bonnet J. Lysyl oxidase deficiency: a new cause of human arterial dissection. Heart 2005, 91:e33.
16. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11:1330-1338.
17. Payne S.L., Hendrix M.J., Kirschmann D.A. Paradoxical roles for lysyl oxidases in cancer-a prospect. J. Cell. Biochem. 2007, 101:1338-1354.
18. Martinez-Martinez E., Miana M., Jurado-Lopez R., Bartolome M.V., Souza Neto F.V., Salaices M., et al. The potential role of leptin in the vascular remodeling associated with obesity. Int. J. Obes. 2014, 38:1565-1572.
19. Martinez-Martinez E., Jurado-Lopez R., Valero-Munoz M., Bartolome M.V., Ballesteros S., Luaces M., et al. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J. Hypertens. 2014, 32:1104-1114.
20. Tang S.S., Chichester C.O., Kagan H.M. Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors. Connect. Tissue Res. 1989, 19:93-103.
21. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334:292-295.
22. Schram K., Sweeney G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc. Med. 2008, 18:199-205.
23. Cavalera M., Wang J., Frangogiannis N.G. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl. Res. 2014, 164:323-335.
24. Eschalier R., Rossignol P., Kearney-Schwartz A., Adamopoulos C., Karatzidou K., Fay R., et al. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014, 63:740-746.
25. de las Heras N., Martin-Fernandez B., Miana M., Ballesteros S., Oubina M.P., Lopez-Farre A.J., et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J. Hypertens. Suppl. 2009, 27:S37-S41.
26. Orriols M., Guadall A., Galan M., Marti-Pamies I., Varona S., Rodriguez-Calvo R., et al. Lysyl oxidase (LOX) in vascular remodelling. Insight from a new animal model. Thromb. Haemost. 2014, 112:812-824.
27. Hermida N., Markl A., Hamelet J., Van Assche T., Vanderper A., Herijgers P., et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc. Res. 2013, 99:44-54.
28. Zibadi S., Vazquez R., Moore D., Larson D.F., Watson R.R. Myocardial lysyl oxidase regulation of cardiac remodeling in a murine model of diet-induced metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H976-H982.
29. Stefanon I., Valero-Munoz M., Fernandes A.A., Ribeiro R.F., Rodriguez C., Miana M., et al. Left and right ventricle late remodeling following myocardial infarction in rats. PLoS One 2013, 8:e64986.
30. Lopez B., Gonzalez A., Lindner D., Westermann D., Ravassa S., Beaumont J., et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. Cardiovasc. Res. 2013, 99:111-120.
31. Lopez B., Querejeta R., Gonzalez A., Larman M., Diez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012, 60:677-683.
32. Adam O., Theobald K., Lavall D., Grube M., Kroemer H.K., Ameling S., et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J. Mol. Cell. Cardiol. 2011, 50:678-685.
33. Maki J.M., Rasanen J., Tikkanen H., Sormunen R., Makikallio K., Kivirikko K.I., et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002, 106:2503-2509.
34. Hornstra I.K., Birge S., Starcher B., Bailey A.J., Mecham R.P., Shapiro S.D. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J. Biol. Chem. 2003, 278:14387-14393.
35. Nave A.H., Mizikova I., Niess G., Steenbock H., Reichenberger F., Talavera M.L., et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1446-1458.
36. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
37. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
38. Kothapalli D., Liu S.L., Bae Y.H., Monslow J., Xu T., Hawthorne E.A., et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012, 2:1259-1271.
39. Kato S., Spinale F.G., Tanaka R., Johnson W., Cooper G., Zile M.R. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. The American Journal of Physiology 1995, 269:H863-H868.
40. Ohmura H., Yasukawa H., Minami T., Sugi Y., Oba T., Nagata T., et al. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice. Hypertens. Res. 2012, 35:1063-1068.
41. Pez F., Dayan F., Durivault J., Kaniewski B., Aimond G., Le Provost G.S., et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011, 71:1647-1657.
42. Voloshenyuk T.G., Hart A.D., Khoutorova E., Gardner J.D. TNF-alpha increases cardiac fibroblast lysyl oxidase expression through TGF-beta and PI3Kinase signaling pathways. Biochem. Biophys. Res. Commun. 2011, 413:370-375.
43. Biernacka A., Cavalera M., Wang J., Russo I., Shinde A., Kong P., et al. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circulation Heart Failure 2015, 8:788-798.
44. Burla A.K., Lobato N.S., Fortes Z.B., Oigman W., Neves M.F. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int. J. Cardiol. 2013, 165:483-487.
45. Campbell D.J., Somaratne J.B., Jenkins A.J., Prior D.L., Yii M., Kenny J.F., et al. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc. Diabetol. 2011, 10:80.
46. Stevens A.L., Ferferieva V., Bito V., Wens I., Verboven K., Deluyker D., et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats. Int. J. Cardiol. 2015, 186:154-160.
47. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 2008, 51:93-102.